Caristo provides AI-powered cardiovascular diagnostic solutions for early detection and prevention of heart attacks.

Caristo

Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions.

Our Website: https://www.caristo.com

Follow us on Twitter: https://twitter.com/CaristoHeart

Longwall Venture Partners

Oxford Science Enterprises

Oxford Investment Consultants LLP

Caristo Diagnostics

We’re gearing up for #ESC2024 in London! 
📅 Save the Date: Join us at our satellite symposium to explore groundbreaking insights into coronary artery disease prevention through the lens of coronary inflammation. Learn more - https://lnkd.in/dkb8u5hu 

💬 Meet Us at ESC: Book a meeting at booth C600 to meet the Caristo Medical and Business team and discover our innovative CaRi-Heart Technology. 
Schedule a booth appointment - https://lnkd.in/e9FD6ZQm 

European Society of Cardiology, Prof Peter Libby, Prof John Deanfield CBE, Prof Ron Blankstein, Prof Charalambos Antoniades, Harvard Medical School, Brigham and Women's Hospital, University of Oxford

#Prevention #Cardiovasculardisease #heartattack #FAIScore #coronaryinflammation

We had an incredible symposium chaired by Prof. Peter Libby, Brigham and Women's Hospital and Harvard Medical School, and Prof. John Deanfield CBE, University College London, at #ESC2024. Highlights included excellent presentations from Prof. Ron Blankstein (Brigham and Women's Hospital and Harvard Medical School) and Prof. Charalambos Antoniades (University of Oxford) on the evolution of CAD diagnosis, shifting from stenosis to coronary inflammation, as measured by the FAI-Score. Thank you all for joining us. 

To learn more about the FAI-Score, visit us at the Caristo booth #C600! 

Discover more - https://lnkd.in/dZQb6927 
European Society of Cardiology #FAIScore #CoronaryInflammation #CardiovascularDisease #Prevention #HeartDisease #HeartAttackRisk

Caristo at #ESC2024 in London!  
💡 Attend our symposium to explore groundbreaking insights into coronary artery disease prevention through the lens of coronary inflammation.  
👉 Meet us at booth C600 to discover our innovative CaRi-Heart Technology. https://bit.ly/3VL3acQ 

#CoronaryInflammation #FAIScore #MedicalInnovation #Healthcare #Congress #Imaging

We were delighted to welcome Dr. Andrew Mitchell, Consultant Cardiologist at Jersey General Hospital and Honorary Consultant at Oxford University Hospitals NHS Foundation Trust, to our Oxford HQ this week. Our product, clinical, and business teams had engaging and productive discussions with him. We look forward to expanding access to CaRi-Heart, ensuring even more patients in the Channel Islands of Jersey benefit from our innovative solution. 

💡 Learn more about CaRi-Heart Technology on our website - https://lnkd.in/euTKa2im

#CoronaryInflammation #FAIScore #MedicalInnovation #Healthcare

We're #hiring a new Image Analyst in Oxfordshire, England. Apply today or share this post with your network.

Excellent news Dr Murray, having researched this technology, this is a game changer , moving to an absolute risk, as opposed to using existing models that can under estimate risk is essential given cardiovascular disease is the leading cause of mortality, looomg forward to our collaboration

Metric
Company Name	Caristo
Symbol
MSH ID	COM:CARISTO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Technology
Country	GB
Stage
Employee Count	43
Website	caristo.com
LinkedIn	caristo
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CARI

COM:CARISTO

Caristo

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue